• Hexa His Tag Peptide: Advanced Workflows and Decision Scienc

  2026-05-09

  Explore the Hexa His tag peptide’s unique role in protein purification and immunoprecipitation workflows. This article goes beyond mechanism, offering a decision-oriented guide to optimizing 6X His tag peptide use in recombinant protein research.

• Tunable Human Intestinal Organoids: Balancing Renewal and Di

  2026-05-09

  This study introduces a human intestinal organoid system that achieves precise and reversible control over the balance between stem cell self-renewal and differentiation. By combining small molecule pathway modulators, the researchers overcome previous limitations of cellular homogeneity and restricted proliferative capacity, enabling scalable and diverse organoid cultures with broad implications for disease modeling and high-throughput applications.

• Tigecycline: Glycylcycline Antibiotic Workflows for Resistan

  2026-05-08

  Tigecycline, a pioneering glycylcycline antibiotic, empowers researchers to tackle multidrug-resistant bacteria with robust, reproducible workflows. This article delivers protocol optimizations, troubleshooting strategies, and insights rooted in current resistance gene dynamics—bridging in vitro, in vivo, and translational research.

• Cell Death Mechanisms Drive Liver Disease Progression

  2026-05-07

  Luedde et al. provide a comprehensive review of how diverse cell death modalities—apoptosis, necrosis, and necroptosis—influence the onset and progression of liver diseases, including fibrosis and hepatocellular carcinoma. The work highlights the clinical significance of monitoring hepatocyte death and delineates molecular pathways as potential therapeutic targets.

• L-NAME Hydrochloride in Vascular Tone Regulation Studies

  2026-05-07

  L-NAME Hydrochloride is a gold-standard NOS inhibitor for probing nitric oxide’s role in vascular function, cardiovascular disease models, and inflammation signaling. This article delivers practical workflow enhancements, troubleshooting strategies, and connects recent anti-inflammatory mechanistic insights to optimize your research with APExBIO’s trusted reagent.

• Toremifene Citrate: Molecular Precision in Estrogen Receptor

  2026-05-06

  Explore the molecular precision and advanced research applications of Toremifene Citrate, an oral selective estrogen receptor modulator. This in-depth analysis goes beyond standard protocols, revealing how nuanced pharmacology and assay design with Toremifene Citrate can drive innovation in estrogen receptor signaling and breast cancer research.

• Dual-Action Inhibition of p38α MAPK: Structural Insights and

  2026-05-06

  This study uncovers how certain kinase inhibitors not only block the active site of p38α MAP kinase but also accelerate its dephosphorylation by the WIP1 phosphatase. By determining crystal structures of inhibitor-bound p38α, the research provides a mechanistic basis for dual-action inhibition, opening new avenues for the design of more potent and specific kinase inhibitors.

• Prostaglandin E2 in Inflammation Research: Workflows & Troub

  2026-05-05

  Prostaglandin E2 (PGE2) is a pivotal tool for dissecting immune regulation and gastrointestinal mucosal protection. This guide empowers researchers with actionable protocols, troubleshooting advice, and translational insights to maximize PGE2’s impact in advanced inflammation and reproductive medicine studies.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-05-05

  Yi et al. present evidence that lysine-87 lactylation of aldolase B (ALDOB) orchestrates mitochondrial fission and metabolic reprogramming in pulmonary hypertension, via a lactate–ALDOB–DRP1 axis. Their work clarifies a previously uncharacterized mechanism linking metabolic shifts to pathological vascular remodeling and highlights potential intervention points.

• Tankyrase Inhibition Suppresses HCC Growth via Hippo Pathway

  2026-05-04

  Jia et al. (2017) demonstrate that selective tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell growth by downregulating YAP activity through stabilization of AMOTL1/2, thereby modulating the Hippo pathway. These findings provide mechanistic insight into targeting tankyrase for cancer therapy and highlight the intersection between Wnt/β-catenin and Hippo signaling in tumor suppression.

• Entinostat (MS-275): Precision HDAC1/3 Inhibition in Cancer

  2026-05-04

  Entinostat (MS-275) empowers researchers with selective, potent HDAC1 and HDAC3 inhibition, proven to modulate cancer cell proliferation and apoptosis. This guide translates advanced in vitro findings and clinical strategies into actionable workflows, troubleshooting, and comparative context for maximizing HDAC inhibitor research impact.

• Pharmacokinetic Variability of CSBTA in MASH: Insights for R

  2026-05-03

  This study systematically characterizes the pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). By integrating transporter and metabolic enzyme profiling, the research uncovers how pathological status in MASH alters systemic and hepatic exposure of key alkaloids, informing rational dosing strategies for future MASLD/MASH studies.

• ATRX-Deficient Glioma Sensitivity to Multi-Targeted RTK Inhi

  2026-05-02

  This study uncovers that high-grade glioma cells lacking ATRX are markedly more susceptible to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The findings highlight the importance of ATRX status in therapeutic stratification and suggest combinatorial treatment strategies may be more effective in this aggressive cancer subtype.

• Disrupting c-MYC/G9a Axis: BRD4-RAC1 Co-Inhibition in Breast

  2026-05-02

  The referenced study demonstrates that co-targeting BET bromodomain BRD4 and RAC1 signaling suppresses breast cancer growth and stemness by disrupting the c-MYC-G9a-FTH1 axis and modulating HDAC1. This combinatorial approach reveals epigenetic vulnerabilities and offers a mechanistic basis for new therapeutic strategies in diverse breast cancer subtypes.

• Blocking GCLC Truncation Delays Cataract Formation in Aging

  2026-05-01

  Wei et al. (2024) reveal that preventing age-related truncation of the γ-glutamylcysteine ligase catalytic subunit (GCLC) in mice preserves lens glutathione and significantly delays cataract onset. This mechanistic insight offers a promising molecular target for non-surgical cataract prevention strategies.

556 records 19/38 page Previous Next First page 上5页 1617181920 下5页 Last page